TME Pharma Balance Sheet

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	2.01	3.24	2.25	4.63	9.46
Short-Term Investments	0	0.01	0	-	0.03
Cash & Short-Term Investments	2.02	3.25	2.25	4.63	9.49
Cash Growth	-37.87%	44.54%	-51.55%	-51.17%	-8.16%
Accounts Receivable	0	0	-	-	-
Other Current Assets	0.1	0.12	0.14	0.38	0.21
Total Current Assets	2.12	3.36	2.39	5.01	9.69
Net Property, Plant & Equipment	0.01	0.03	0.1	0.22	0.07
Other Intangible Assets	0	0	0	0	0
Long-Term Investments	0.01	0.01	0.01	0.01	-
Total Assets	2.14	3.41	2.49	5.24	9.77
Accounts Payable	0.8	1.33	1.17	1.7	2.24
Short-Term Debt	-	-	1.21	4.14	2.51
Current Portion of Long-Term Debt	2.66	0.06	-	-	-
Current Portion of Leases	-	-	0.07	0.11	0.02
Other Current Liabilities	0.26	0.41	0.34	0.5	0.51
Total Current Liabilities	3.72	1.79	2.79	6.45	5.27
Long-Term Leases	-	-	-	0.07	-
Total Long-Term Liabilities	-	-	-	0.07	0
Total Liabilities	3.72	1.79	2.79	6.51	5.27
Common Stock	0.94	0.94	0.17	1.74	0.75
Treasury Stock	-0.22	-0.23	-0.22	-0.22	-0.19
Additional Paid-in Capital	201.07	200.98	194.12	184.84	176.46
Accumulated Other Comprehensive Income	0.01	0.01	0.01	0.01	0.01
Retained Earnings	-203.38	-200.09	-194.37	-187.64	-172.5
Total Common Shareholders' Equity	-1.58	1.61	-0.29	-1.27	4.52
Minority Interest	-	-	-	0	-0.01
Shareholders' Equity	-1.58	1.61	-0.29	-1.27	4.5
Total Liabilities & Equity	2.14	3.41	2.49	5.24	9.77
Total Debt	2.66	0.06	1.28	4.32	2.53
Net Cash (Debt)	-0.64	3.19	0.97	0.31	6.96
Net Cash Growth	-	230.12%	207.64%	-95.49%	-27.80%
Net Cash Per Share	-0.01	0.09	0.19	0.27	10.55
Book Value	-1.58	1.61	-0.29	-1.27	4.52
Book Value Per Share	-0.02	0.04	-0.06	-1.08	6.84
Tangible Book Value	-1.58	1.61	-0.3	-1.28	4.51
Tangible Book Value Per Share	-0.02	0.04	-0.06	-1.08	6.84